Welcome to our dedicated page for Cannapharmarx news (Ticker: CPMD), a resource for investors and traders seeking the latest updates and insights on Cannapharmarx stock.
CannaPharmaRX, Inc. reports developments in cannabis cultivation and international export operations. The company operates cannabis production activities in Alberta and has described shipments, purchase orders, harvest activity and distribution relationships tied to medical cannabis markets including Israel and Germany.
Recurring updates for CPMD include facility utilization, cannabis strain development, product quality and THC-related pricing, inventory preparation, export licensing, quarterly financial results and balance-sheet initiatives. Company news also covers Canadian regulatory matters, including continuous-disclosure issues with the British Columbia Securities Commission.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
CannaPharmaRx (OTC PINK:CPMD) has signed a Memorandum of Understanding (MOU) with Nasha Genetics to enhance its presence in the medical cannabis sector. Nasha, recognized for its cannabis strain genetics, will supply CPMD with genetics that can produce high-quality cannabis with at least 20% THC. Under the agreement, Nasha will manage costs related to the genetic supply, while CannaPharmaRx will handle cultivation within 10 days of receiving the genetics. The partnership allows for a 7.5-year term during which Nasha will order at least 400 KG of cannabis from CannaPharmaRx, which will seek necessary export licenses for markets beyond Israel. A definitive agreement is expected within 45 days.